Tiger Brokers

Dyadic International FY2025 net loss widens 26.68% to $7.36 million; revenue drops 11.71% to $3.09 million

Reuters
Yesterday
Dyadic International FY2025 net loss widens 26.68% to $7.36 million; revenue drops 11.71% to $3.09 million
  • Dyadic filed a Form 8-K reporting 2025 results, with total revenue down 11.71% to USD 3.09 million, driven mainly by fewer active collaborations that reduced research and development revenue.
  • License and milestone revenue fell 85.98% to USD 265,000, while grant revenue increased by USD 1.86 million on higher funding from the Gates Foundation and CEPI.
  • Loss from operations widened 21.86% to USD 7.19 million and net loss increased 26.68% to USD 7.36 million, or USD 0.23 per share.
  • Cash, cash equivalents, restricted cash and investment-grade securities totaled USD 8.59 million at year-end, down 7.54%.
  • Recent updates included Proliant’s commercial launch of AlbuFree DX recombinant human albumin and an OEM distribution agreement with IBT Bioservices to commercialize recombinant DNase I and transferrin through IBT’s global channels.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyadic International Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-012673), on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10